目的 觀察醒腦靜注射液聯(lián)合阿托伐他汀治療急性腦出血的臨床療效。方法 選取2013年1月-2014年12月延安大學(xué)咸陽醫(yī)院收治的急性腦出血患者120例,隨機(jī)分為對照組和治療組,每組各60例。對照組患者在常規(guī)治療的基礎(chǔ)上口服阿托伐他汀鈣片,20 mg/次,1次/d。治療組患者在對照組的治療基礎(chǔ)上靜脈滴注醒腦靜注射液,20 mL/次,以生理鹽水500 mL稀釋后滴注,2次/d。兩組均連續(xù)治療12周。觀察兩組的臨床療效,比較兩組治療過程中C反應(yīng)蛋白(CRP)、白細(xì)胞介素1β(IL-1β)、腫瘤壞死因子α(TNF-α)、一氧化氮(NO)、丙二醛(MDA)、超氧化物歧化酶(SOD)活性以及神經(jīng)功能缺損(NIHSS)評分的變化情況。結(jié)果 治療后,對照組和治療組的總有效率分別為73.33%、88.33%,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P < 0.05)。治療后,兩組CRP、IL-1β、TNF-α、MDA、NO、NIHSS評分均顯著降低,SOD顯著升高,同組治療前后差異具有統(tǒng)計(jì)學(xué)意義(P < 0.05);且治療組這些觀察指標(biāo)的改善程度優(yōu)于對照組,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P < 0.05)。結(jié)論 醒腦靜注射液聯(lián)合阿托伐他汀治療急性腦出血具有較好的臨床療效,可降低炎癥相關(guān)因子和NIHSS評分,具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical efficacy of Xingnaojing Injection combined with atorvastatin in treatment of acute cerebral hemorrhage. Methods Patients (120 cases) with acute cerebral hemorrhage in Xianyang Hospital of Yan'an University from January 2013 to December 2014 were randomly divided into control and treatment groups, and each group had 60 cases. The patients in the control group were po administered with Atorvastatin Calcium Tablets on the basis of conventional treatment, 20 mg/time, once daily. The patients in the control group were iv administered with Xingnaojing Injection, 20 mL/time, which was added into normal saline 500 mL, twice daily. Two groups were treated for 12 weeks. After treatment, the efficacy was evaluated, and the changes of CRP, IL-1β, TNF-α, NO, MDA, SOD, and NIHSS scores in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 73.33% and 88.33%, respectively, and there were differences between two groups (P < 0.05). After treatment, CRP, IL-1β, TNF-α, MDA, NO, and NIHSS scores were significantly decreased, and SOD was significantly increased, and the difference was statistically significant in the same group (P < 0.05). These observational indexes in the treatment group were better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Xingnaojing Injection combined with atorvastatin has good clinical curative effect in treatment of acute cerebral hemorrhage, and can reduce the inflammation related factors and NIHSS scores, which has a certain clinical application value.